Castle Biosciences (CSTL) Form 4 Filings

CASTLE BIOSCIENCES INC Chief Commercial Officer Juvenal Tobin reported an open-market sale of 20,863 shares of common stock. The shares were sold at a weighted-average price of $25.24 per share, with individual trade prices ranging from $24.90 to $25.70. After this transaction, Tobin directly holds 86,825 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the timing was set in advance rather than decided opportunistically.

Castle Biosciences President and CEO Derek J. Maetzold reported a pre-planned combination of option exercise and share sales. On March 11, 2026, he exercised a fully vested stock option for 6,226 shares of common stock at $2.39 per share and received the underlying shares.

That same day, Maetzold and several family-related trusts sold multiple blocks of common stock in open-market transactions at a weighted-average price of about $26.11. On March 12, 2026, he sold an additional 23,179 shares at an average price of $25.279 per share. All sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025. After these trades, he holds 71,558 shares directly, plus additional indirect holdings through various trusts.

Castle Biosciences Chief Financial Officer Frank Stokes sold 6,001 shares of common stock on March 5, 2026 in an open-market transaction at a weighted-average price of $27.98 per share. The sale was made under a prearranged Rule 10b5-1 trading plan adopted on November 13, 2025.

The transaction was executed in multiple trades at prices ranging from $27.51 to $28.41 per share, with the reported price reflecting the weighted average. After this planned sale, Stokes continues to directly own 60,085 shares of Castle Biosciences common stock.

Castle Biosciences director Cole G Bradley reported option exercises and stock sales. On March 5, 2026, Bradley exercised stock options for 4,748 shares and received an equal number of common shares. He then sold a total of 7,403 common shares in open-market transactions and held 19,309 shares directly afterward.

Castle Biosciences Chief Commercial Officer Juvenal Tobin W reported several equity compensation transactions in early March 2026. On March 3, he received a grant of 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, which will vest in four equal annual installments beginning March 3, 2027.

On March 4, previously granted RSUs were exercised into common stock, and 10,399 shares and 3,716 shares of common stock were withheld to cover tax obligations in connection with vested performance or restricted stock units. After these transactions, his directly held common stock and RSU positions increased overall.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported several equity compensation transactions involving restricted stock units (RSUs) and common stock. On March 3, 2026, she received a grant of 48,367 RSUs, which vest in four equal annual installments beginning on March 3, 2027.

On March 4, 2026, she exercised or converted RSUs covering 13,811 and 11,960 RSUs at a price of $0.00 per unit, resulting in 25,771 shares of common stock acquired through derivative exercises. The filing also reports dispositions of 6,792 and 2,427 shares of common stock at $28.17 and $27.57 per share, respectively, to satisfy tax withholding obligations in connection with vested performance stock units.

Following these transactions, she holds common stock directly and also has an indirect holding of 97,251 shares of common stock through The Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries. Each RSU represents the right to receive one share of Castle Biosciences common stock.

Castle Biosciences president and CEO Derek J. Maetzold reported several equity compensation transactions in company stock. On March 3, 2026, he received a grant of 102,597 Restricted Stock Units (RSUs), which, according to a footnote, vest in four equal annual installments beginning on March 3, 2027.

On March 4, 2026, RSUs previously granted were converted into a total of 59,097 shares of common stock through derivative exercises. On March 3 and March 4, 2026, a combined 36,974 shares of common stock were disposed of at prices of $27.57 and $28.17 per share to satisfy tax withholding obligations.

The filing also lists indirect holdings of common stock in multiple trusts, including The Maetzold Descendants 2020 Trust and several Maetzold remainder and grantor retained annuity trusts, where Maetzold or his spouse serves as trustee and certain family members are beneficiaries.

Castle Biosciences Chief Financial Officer Frank Stokes reported a mix of stock awards, option exercises, sales, and tax-related share withholdings. On March 3, 2026, he was granted 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in four equal annual installments beginning March 3, 2027.

That same day, he sold 5,300 and 1,700 shares of common stock at weighted-average prices of $27.32 and $27.81 in open-market transactions under a Rule 10b5‑1 trading plan. He also disposed of 3,611 shares at $27.57 to cover tax withholding on previously vested performance stock units.

On March 4, 2026, Stokes exercised derivative awards, converting 12,186 and 11,960 RSUs and 3,800 fully vested stock options into common stock, including 3,800 shares at an exercise price of $3.38. After these transactions, he directly owned 66,086 common shares, including 1,033 shares acquired under the employee stock purchase plan.

Castle Biosciences president and CEO Derek J. Maetzold sold 4,017 shares of common stock in early February 2026 under a pre-arranged Rule 10b5-1 trading plan. Sales included 3,200 shares on February 3 at a weighted-average price of $39.913 and two sales on February 4 totaling 817 shares at weighted-average prices of $37.822 and $38.61. After these transactions, he directly held 83,698 common shares. He also reported indirect beneficial ownership of additional Castle Biosciences shares through multiple family and grantor retained annuity trusts.

Castle Biosciences Inc.’s President and Chief Executive Officer, Derek J. Maetzold, reported a planned sale of common stock under a pre-established Rule 10b5-1 trading plan. On January 20, 2026, he sold 4,017 shares of common stock at a weighted-average price of $40.013 per share in multiple trades within a disclosed price range.

Following this sale, Maetzold directly holds 87,715 shares of Castle Biosciences common stock, and additional shares are held indirectly through various family and grantor retained annuity trusts for which he or his spouse serves as trustee or beneficiary. The filing reflects an orderly, pre-planned diversification step rather than an ad hoc transaction.

Castle Biosciences reported that President and CEO Derek J. Maetzold received equity awards tied to performance. On January 12, 2026, 62,219 performance-based stock units (PSUs) granted on March 4, 2024 vested after the board certified that specific performance criteria were met. Each PSU converts into one share of common stock, so Maetzold acquired 62,219 shares of common stock at $0 per share, bringing his directly held common stock to 91,732 shares.

The filing also lists additional common stock held indirectly through various family and grantor retained annuity trusts for estate and family planning purposes. A remaining block of 62,219 PSUs from the 2024 grant is still outstanding and will vest only if stated milestones are achieved.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported equity awards tied to performance. On January 12, 2026, she received 9,207 Performance-Based Stock Units (PSUs), each representing the right to one share of common stock at a price of $0. On the same date, 9,207 shares of common stock were acquired at $0 upon vesting of 50% of PSUs granted on March 4, 2024, after the board certified that performance criteria were met.

Following these transactions, she directly holds 21,530 shares of Castle Biosciences common stock and indirectly holds 97,251 shares through The Fritz Shorter Trust, where she and her spouse are trustees and beneficiaries. The reported PSUs represent the remaining 50% of the 2024 performance-based grant, which will vest only if additional milestones are achieved.

Castle Biosciences reported that Chief Commercial Officer Juvenal Tobin received common stock as performance-based compensation. On January 12, 2026, 9,207 Performance-Based Stock Units (PSUs) from a grant made on March 4, 2024 vested after the board certified that certain performance criteria were met.

Each PSU converts into one share of Castle Biosciences common stock, so 9,207 shares of common stock were acquired at a price of $0 per share. Following this transaction, Tobin beneficially owned 96,032 shares of common stock directly, and 9,207 PSUs remain outstanding, which will vest only if additional milestones are achieved.

Castle Biosciences Chief Financial Officer Frank Stokes reported equity awards tied to performance-based stock units. On 01/12/2026, 8,124 Performance-Based Stock Units (PSUs) granted on March 4, 2024 vested after the board certified that certain performance criteria were met, resulting in the acquisition of 8,124 shares of common stock at a price of $0 per share.

These vested PSUs represent 50% of the 2024 PSU grant. The remaining 50% of the 2024 PSUs, representing an additional 8,124 PSUs, will vest only if specified milestones are achieved. Following the transaction, Stokes beneficially owns 58,450 shares of common stock directly and 8,124 PSUs.

Castle Biosciences Inc. insider activity: President, Chief Executive Officer and director Derek J. Maetzold reported open-market sales of common stock under a Rule 10b5-1 trading plan adopted on May 8, 2025. He sold 2,678 shares on January 5, 2026 at a weighted-average price of $38.09 per share and 1,339 shares on January 6, 2026 at a weighted-average price of $40.096 per share, for a total of 4,017 shares sold.

After these transactions, Maetzold directly held 29,513 shares of common stock. He also reported indirect beneficial ownership through multiple trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust, 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust, several 2018 remainder trusts each holding 3,615 or 3,618 shares, and 85,959, 18,718 and 44,323 shares held by DJM Grantor Retained Annuity Trusts Nos. 5, 6 and 7, respectively.

Castle Biosciences Inc. reported insider stock sales by its president, chief executive officer and director. On 12/15/2025, the reporting person sold 18,513 shares of common stock at a weighted-average price of $38.747 and 1,012 shares at $39.304. On 12/16/2025, they sold an additional 12,821 shares at a weighted-average price of $38.554. These trades were made under a Rule 10b5-1 trading plan adopted on May 8, 2025. After the reported sales, the reporting person directly owns 34,869 shares of common stock and also has indirect beneficial ownership of multiple blocks of shares through several family and grantor retained annuity trusts.

Castle Biosciences’ chief commercial officer reported selling 13,200 shares of the company’s common stock on 12/11/2025 at a weighted-average price of $37.48 per share. The transaction is disclosed as a sale of non-derivative securities on a Form 4 filing.

Following this sale, the officer directly beneficially owns 86,825 shares of Castle Biosciences common stock. The filing notes that the transaction was executed in multiple trades at prices ranging from $37.31 to $37.72 per share, with the reported price reflecting the weighted-average sale price.

Castle Biosciences' chief financial officer reported an insider stock sale. On 12/11/2025, the officer sold 4,496 shares of common stock at $37.45 per share, leaving 50,326 shares owned directly after the transaction.

Castle Biosciences’ president, chief executive officer and director reported multiple stock transactions tied to restricted stock unit (RSU) vesting. On December 9, 2025, RSUs converted into 33,495 shares of common stock, followed by the disposition of 13,181 shares at $38.25 per share to cover tax obligations. On December 10, 2025, additional RSUs converted into 15,424 shares, with 6,070 shares disposed of at $38.02 per share for taxes, leaving 67,215 shares of common stock held directly.

The reporting person also lists indirect beneficial ownership in Castle Biosciences common stock through several family and grantor retained annuity trusts, each holding separate blocks of shares for the benefit of the reporting person, spouse and children.

Castle Biosciences' Chief Commercial Officer reported equity transactions involving restricted stock units and common stock. On December 9, 2025 and December 10, 2025, the reporting person acquired 15,961 and 6,170 shares of common stock coded "M" in connection with restricted stock units, and disposed of 6,441 and 2,490 shares coded "F" at prices of $38.25 and $38.02 per share.

After these transactions, the officer beneficially owned 100,025 shares of Castle Biosciences common stock directly. The filing also shows 15,961 restricted stock units outstanding from a grant made on December 9, 2022 that vests in four equal installments beginning on December 9, 2023, and notes that 24,679 restricted stock units granted on December 10, 2021 vest in four equal installments beginning on December 10, 2022. The ownership total includes 2,230 shares that were previously held by a family revocable trust and were distributed to the reporting person on February 5, 2025.

Castle Biosciences Inc. reported an insider stock sale by a director who also serves as president and chief executive officer. On December 4, 2025, the insider sold 1,339 shares of common stock at a weighted-average price of $40.03 per share in a transaction made under a contract, instruction or written plan intended to satisfy Rule 10b5-1(c), which was adopted on May 8, 2025.

After this sale, the insider directly owned 37,547 shares of Castle Biosciences common stock and reported additional indirect holdings through several family trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust.

Castle Biosciences, Inc. reported an insider stock sale by a senior executive. The company’s president and chief executive officer, who is also a director, filed a Form 4 showing the sale of 5,115 shares of common stock on 11/25/2025 at a weighted-average price of $40.049 per share.

The filing states that this transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2025. Following the sale, the executive directly owns 45,822 shares of Castle Biosciences common stock. In addition, the executive reports indirect ownership through several family and grantor retained annuity trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 85,959 shares held by DJM Grantor Retained Annuity Trust No. 5, among other trust holdings.

Castle Biosciences (CSTL) reported insider activity by its Chief Commercial Officer. On 11/20/2025, the officer exercised a stock option to buy 4,693 shares of common stock at $3.38 per share and on the same day sold 4,693 shares in open-market transactions at a weighted-average price of $35.58, with individual trades ranging from $35.40 to $35.85. These trades were carried out under a Rule 10b5-1 trading plan adopted on September 11, 2024.

After the transactions and a 68-share reconciliation adjustment, the officer beneficially owns 84,595 shares directly and 2,230 shares indirectly through a family revocable trust. The officer also holds 11,210 fully vested stock options with a $3.38 exercise price expiring on March 12, 2029.

Castle Biosciences Inc. insider trading report: A reporting person who serves as a director and as President & Chief Executive Officer of Castle Biosciences (CSTL) sold 2,678 shares of common stock on 11/18/2025 at a weighted-average price of $34.02 per share. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2025. After this transaction, the insider directly holds 50,937 shares of common stock and also reports indirect ownership through multiple family and grantor retained annuity trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust.

Castle Biosciences (CSTL) reported insider transactions by its Chief Commercial Officer on an amended Form 4. On 11/11/2025, the officer exercised stock options at $3.38 and sold 500 shares at a weighted-average sale price of $35.39. On 11/12/2025, the officer exercised options at $3.38 and sold 200 shares at $35.40. These trades were made under a Rule 10b5-1 plan adopted on September 11, 2024.

Following the transactions, beneficial ownership was 84,527 shares direct and 2,230 shares indirect held by a family revocable trust. Derivative securities beneficially owned after the reported transactions were 15,903 stock options expiring on 03/12/2029. The amendment notes the option exercises were inadvertently omitted from the original filing and are now reported.

Castle Biosciences (CSTL) Form 4: Chief Financial Officer Frank Stokes reported an open-market sale of 5,388 shares of common stock on 11/11/2025 at a weighted-average price of $35.08. The filing notes multiple trades executed between $34.44 and $35.37. Following the transaction, Stokes beneficially owns 43,328 shares, held directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/12/2025.

Castle Biosciences (CSTL) reported an insider transaction by its Chief Commercial Officer on Form 4. The officer sold 500 shares of common stock on 11/11/2025 at a weighted-average price of $35.39 pursuant to a Rule 10b5-1 plan adopted on September 11, 2024. A separate sale of 200 shares occurred on 11/12/2025 at $35.40.

Following these transactions, the officer reported 84,027 shares held directly. In addition, 2,230 shares are held indirectly by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the officer and spouse are trustees and beneficiaries include the officer, spouse, and their children.

Castle Biosciences (CSTL) reported an insider transaction by its Chief Operating Officer. On November 11, 2025, the COO sold 18,932 shares of common stock (code S) under a Rule 10b5-1 plan adopted on March 6, 2025 at a $35.10 weighted-average price, with trade prices ranging from $35.00 to $35.37.

Following the transactions, the reporting person beneficially owns 12,323 shares directly and 97,251 shares indirectly via The Fritz Shorter Trust. The filing also notes a transfer of 3,686 shares from the trust to direct holdings on November 11, 2025.

Castle Biosciences (CSTL) reported insider transactions by President & CEO and Director Derek Maetzold. Under a Rule 10b5-1 plan adopted on May 8, 2025, he sold 6,458 shares on 11/04/2025 at a weighted-average price of $30.413, 237 shares on 11/04/2025 at $31.117, and 2,678 shares on 11/05/2025 at $31.851.

Following these sales, he held 53,615 shares directly. He also reports indirect holdings through family trusts, including 85,959 shares in DJM Grantor Retained Annuity Trust No. 5.

Castle Biosciences (CSTL) disclosed that its Chief Operating Officer reported an open-market sale of 12,678 shares of common stock on 10/31/2025 at a weighted-average price of $25.04, executed in multiple trades within a $25.00–$25.12 range. The sale was made pursuant to a Rule 10b5-1 plan adopted on March 6, 2025.

Following the transaction, the reporting person beneficially owns 27,569 shares directly and 100,937 shares indirectly through The Fritz Shorter Trust.

Castle Biosciences (CSTL): Form 4/A amendment reports that the Chief Operating Officer sold 18,007 shares of common stock on 08/27/2025 at a weighted-average price of $21.69, with trades executed between $21.24 and $21.94. The amendment clarifies the sale was made by the Fritz Shorter Trust, not directly by the executive.

Following the sale, holdings were 52,924 shares held directly and 100,937 shares held indirectly through the Trust. The filing also notes prior transfers to the Trust of 96,322 shares on March 19, 2025 and 22,622 shares on August 22, 2025.